EGFR and glioblastoma: Additionally, depatuxizumab mafodotin (ABT-414), a monoclonal antibody-drug combination, inhibits EGFR amplification in glioblastoma and blocks tubulin polymerization through the tubulin inhibitor monomethyl auristatin F, further combating the tumor [27].